Prescription Drug Affordability Review Board
Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
- PDAB Members
- Dr. Sami Diab, MD
- Dr. Amy Gutierrez, PharmD
- Catherine Harshbarger, RN, MHA
- Board Chair, Dr. Gail Mizner, MD, FACP, AAHIVS
- Dr. James Justin VandenBerg, PharmD, BCPS
- PDAAC Members
- Kim Bimestefer, Executive Director of HCPF
- Gail DeVore, representing health care consumers
- Open position representing health care consumers
- Dr. Bob Mulch, representing statewide health care advocacy organizations
- PDAAC Chair, Dr. Kimberley Jackson, representing health care consumers living with chronic conditions
- Open position representing labor unions
- PDAAC Vice Chair, Nathan Wilkes, representing employers
- Open position representing carriers
- Marc Reese, representing PBMs
- Dr. Richard Miranda, representing health care professionals with prescribing authority
- Dr. Brett McQueen, representing research organizations
- Katelin Lucariello, representing brand name manufacturers
- Fayez Azeez, representing generic manufacturers
- Dr. Ingrid Pan, representing pharmacists
- Leah Lindahl, representing wholesalers
- Conflicts of Interest
PDAB Conflict of Interest Policy and Procedure
PDAB Conflict of Interest Disclosure
Announcements
- To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
- The Board held its fourth, and final, rulemaking hearing for Enbrel's upper payment limit on October 3, 2025. The adopted UPL rule for Enbrel and additional rulemaking materials can be found below.
- The upcoming PDAAC meeting on October 14, 2025 will be the first stakeholder workgroup session to help identify best practices and developing recommendations for collecting patient information during the affordability review. The workgroup is open to all members of the public. Please register for the meeting here to confirm your workgroup participation.
- PDAAC is currently recruiting new council members to represent labor unions, carriers, and health care consumers. If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.
PDAB Meetings
The next PDAB meeting will be held on Friday, November 14, 2025 from 10 am - 1 pm MT.
Register for November 14 PDAB Meeting
Click here to access 2025 PDAB and PDAAC meeting links and recordings. 2026 PDAB and PDAAC meeting links can be found here. Note: previous meeting materials can be accessed by emailing dora_ins_pdab@state.co.us.
November 14 Meeting Materials
- Agenda: coming soon.
PDAAC Meetings
The next PDAAC meeting will be held on Tuesday, October 14, 2025 from 12- 3 pm MT.
Register for October 14 PDAAC Meeting
Note: earlier meeting materials can be accessed by emailing dora_ins_pdab@state.co.us. PDAAC's adopted policies can be found here.
- October 14 Meeting Agenda
- April 24 Meeting Minutes
- Workgroup Session 1 Participant Guide
- October 14 Meeting Slides: coming soon.
PDAB Rulemaking
The UPL rulemaking for Enbrel began during the May 23 PDAB meeting. On October 3, 2025, the Board concluded the rulemaking hearing and finalized the UPL for Enbrel. The adopted rule can be found below.
For more information on PDAB rulemaking and how to provide testimony during a PDAB rulemaking hearing, please visit the linked PDAB Rulemaking Guide. Following are the documents related to Enbrel's UPL rulemaking hearing:
- Adopted UPL Rule for Enbrel (Etanercept)
- Written Testimonies
- Verbal Testimony Sign Up
- Draft Proposed UPL Rule for Enbrel
- Data Submission Guide
- Confidential Information Submission Process
- UPL Benchmark Data Staff Memo
- Enbrel and Therapeutic Alternatives Benchmark Data
- Enbrel UPL Graph Packet
- Enbrel and Therapeutic Alternatives Price Data Methodology
- UPL Cost-Benefit Analysis & Regulatory Analysis
Providing Public Comment
The PDAB welcomes general public comments during PDAB meetings. Comments are limited to 2 minutes per person. Public comment is not a time for the Board to interact with the public.
- Verbal Public Comment: To provide verbal comments, please fill out the sign up form that will be provided at each meeting. Public comments will be limited to 2 minutes per person.
- Written Public Comment: To provide written comments about general PDAB business or agenda items, please email dora_ins_pdab@state.co.us. Written comments will be accepted up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.
Providing Testimony
Verbal or written testimony occurs only during PDAB rulemaking hearings and will be included in the rulemaking record. The Board may ask questions of stakeholders during their testimony. Visit the PDAB Rulemaking Guide for more information on testifying at a PDAB rulemaking hearing.
- Verbal Testimony: To provide verbal testimony, please fill out the testimony sign up form. Verbal testimony may be limited in duration.
- Written Testimony: please submit written testimony via dora_ins_pdab@state.co.us. Written testimonies will be accepted up to 48 hours before each rulemaking hearing. Comments submitted after the 48-hour deadline will be considered for the following rulemaking hearing.
- PDAB Rules and Policies
- Previous PDAB Meeting Materials
Note: meeting materials not displayed on this website can be accessed by emailing dora_ins_pdab@state.co.us
Meeting Date & Recording Meeting Materials Written Comments/Testimonies October 3, 2025 (Enbrel UPL Rulemaking Hearing 4) Agenda Slides Written Testimonies Written Comments September 29, 2025 Ad Hoc Agenda Minutes N/A August 22, 2025 (Enbrel UPL Rulemaking Hearing 3) Agenda Minutes Slides Written Testimonies July 11, 2025 (Enbrel UPL Rulemaking Hearing 2) Agenda Minutes Slides Written Testimonies Written Comments May 23, 2025 (Enbrel UPL Rulemaking Hearing 1) Agenda Minutes Slides Written Testimonies Written Comments April 11, 2025 Agenda Minutes Slides Written Comments February 21, 2025 Ad Hoc Agenda Minutes N/A January 17, 2025 Agenda Minutes Slides Written Comments 2024 Meeting Recordings (Email dora_ins_pdab@state.co.us to receive previous meeting materials.) - Activities Summary Reports
- 2023/2024 Affordability Review Activities